27th October 2011 GB0001646941/GBP/PLUS-exn EDEN RESEARCH PLC ("Eden" or the "Company") Acquisition of exclusive Licence from University of Massachusetts Medical School * Global Licence agreement signed with University of Massachusetts Medical School, USA * Company has acquired the exclusive rights to a new, "next-generation" encapsulation delivery system * Significant potential for applications such as animal health, biocides and cosmetics Eden Research plc, the agrochemical and encapsulation company, is pleased to announce that it has acquired the exclusive, global rights to a next-generation encapsulation delivery system based on scientific research at the University of Massachusetts Medical School in Worcester, USA ("UMMS"). The UMMS technology will augment Eden's own proprietary technology and allows for greater control over the timing of release of the active substance. The patent covering the new technology has been granted in seven countries to date including USA, Spain, France and Italy and is valid until June 2025, which extends the life of Eden's overall patent position. The patent is also in an advanced state of registration in a number of other countries. Eden's proprietary encapsulation delivery system is already being used commercially in environmentally friendly agrochemical applications where it enables the slow release of compounds to control pests and infection. The system is also being evaluated by some of the world's largest companies for use in other sectors such as animal health, biocides and cosmetics, all of which will benefit from the next-generation UMMS technology. Clive Newitt, Managing Director of Eden, said, "This new, advanced system opens the door to a number of exciting opportunities for Eden as we can now provide a platform for greater precision delivery of active substances which enables dosages to be reduced to meet the demands of consumers, retailers and regulators. We are committed to expanding our portfolio of related technologies and this license will complement the rights recently granted from Cornell University to ensure that Eden is positioned at the fore-front of encapsulation technology." The Directors of Eden are responsible for the contents of this announcement. Enquiries Eden Research plc 01993 862761 Clive Newitt, Managing Director St Helens Capital Partners LLP 020 7368 6959 Mark Anwyl University of Massachusetts Medical School Mark L. Shelton 001-508-856-2000 Notes: Eden has developed terpene-based encapsulation technology which uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are natural compounds which function as defence mechanisms in many plant groups and are released in response to infection, attack by pests, stress or mechanical injury. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries. Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals. The next-generation encapsulation technology licensed from the University of Massachusetts Medical School provides significant additional benefits to the original system as it allows release to be controlled by environmental factors rather than relying solely upon the chemistry of the substances used. This means that there is more control over the timing of the release of the active compound being carried allowing for further reduction in chemicals applied whilst ensuring maximum effectiveness. The UMMS license also significantly expands the potential use of the Eden technology in non-agricultural applications such as health and beauty, cosmetics and animal health. About the University of Massachusetts Medical School: The University of Massachusetts Medical School attracts more than $300 million in research funding annually, and its innovative programs are the centerpiece of the Massachusetts Life Sciences Initiative. Consistently ranked by U.S.News & World Report as one of the leading medical schools in the nation for primary care education, UMMS comprises a medical school, graduate school of nursing, graduate school of biomedical sciences and an active research enterprise, and is a leader in health sciences education, research and public service. For more information about Eden, please visit [ www.edenresearch.com ] For more information about UMMS, please visit [ www.ummassmed.edu ]

Contributing Sources

---

Market Wire